Cargando…

Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China

Increasing evidence has shown an unusual relationship between hypertension and COVID-19, which may not be as simple as previously thought. The purpose of our study was to determine the association of hypertension with the onset and development of COVID-19. A meta-analysis was performed to summarize...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bo, Zeng, Lu, Sun, Nengjun, Zhao, Yunhe, Zhao, Faming, Bian, Hongjun, Yi, Wei, Yang, Jing, Li, Bin, Su, Guohai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685758/
https://www.ncbi.nlm.nih.gov/pubmed/34938578
http://dx.doi.org/10.1155/2021/6594863
_version_ 1784617883247050752
author Li, Bo
Zeng, Lu
Sun, Nengjun
Zhao, Yunhe
Zhao, Faming
Bian, Hongjun
Yi, Wei
Yang, Jing
Li, Bin
Su, Guohai
author_facet Li, Bo
Zeng, Lu
Sun, Nengjun
Zhao, Yunhe
Zhao, Faming
Bian, Hongjun
Yi, Wei
Yang, Jing
Li, Bin
Su, Guohai
author_sort Li, Bo
collection PubMed
description Increasing evidence has shown an unusual relationship between hypertension and COVID-19, which may not be as simple as previously thought. The purpose of our study was to determine the association of hypertension with the onset and development of COVID-19. A meta-analysis was performed to summarize the prevalence of hypertension in COVID-19 patients, as well as the usage of ACEIs/ARBs. Metaregression analyses were used to evaluate the association of hypertension with disease severity and mortality. PubMed and Google Scholar were searched for relevant studies. A total of 42 studies including 14138 patients were enrolled in the study. The proportion of hypertension in COVID-19 patients in China was 17.7% according to the enrolled studies, while it was 6.0% in a study containing 72314 confirmed cases, which are both much lower than in the general population. All of the data from the 11 provinces in China showed the same tendency. The proportions of hypertension were higher in severe/ICU patients and nonsurvivors than in nonsevere/ICU patients and survivors. The metaregression analyses suggested that both disease severity and risk of death were associated with the incidence of hypertension. A total of 27.6% of COVID-19 patients with hypertension received ACEI/ARB therapy. The proportion of deaths in COVID-19 patients with hypertension treated with ACEIs/ARBs was significantly lower than that in nonuse patients treated with ACEIs/ARBs. In conclusion, hypertension may reduce the infection risk of COVID-19 but increase the risk of developing worse clinical outcomes. The use of ACEIs/ARBs may benefit COVID-19 patients with hypertension.
format Online
Article
Text
id pubmed-8685758
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-86857582021-12-21 Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China Li, Bo Zeng, Lu Sun, Nengjun Zhao, Yunhe Zhao, Faming Bian, Hongjun Yi, Wei Yang, Jing Li, Bin Su, Guohai Int J Hypertens Review Article Increasing evidence has shown an unusual relationship between hypertension and COVID-19, which may not be as simple as previously thought. The purpose of our study was to determine the association of hypertension with the onset and development of COVID-19. A meta-analysis was performed to summarize the prevalence of hypertension in COVID-19 patients, as well as the usage of ACEIs/ARBs. Metaregression analyses were used to evaluate the association of hypertension with disease severity and mortality. PubMed and Google Scholar were searched for relevant studies. A total of 42 studies including 14138 patients were enrolled in the study. The proportion of hypertension in COVID-19 patients in China was 17.7% according to the enrolled studies, while it was 6.0% in a study containing 72314 confirmed cases, which are both much lower than in the general population. All of the data from the 11 provinces in China showed the same tendency. The proportions of hypertension were higher in severe/ICU patients and nonsurvivors than in nonsevere/ICU patients and survivors. The metaregression analyses suggested that both disease severity and risk of death were associated with the incidence of hypertension. A total of 27.6% of COVID-19 patients with hypertension received ACEI/ARB therapy. The proportion of deaths in COVID-19 patients with hypertension treated with ACEIs/ARBs was significantly lower than that in nonuse patients treated with ACEIs/ARBs. In conclusion, hypertension may reduce the infection risk of COVID-19 but increase the risk of developing worse clinical outcomes. The use of ACEIs/ARBs may benefit COVID-19 patients with hypertension. Hindawi 2021-12-20 /pmc/articles/PMC8685758/ /pubmed/34938578 http://dx.doi.org/10.1155/2021/6594863 Text en Copyright © 2021 Bo Li et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Li, Bo
Zeng, Lu
Sun, Nengjun
Zhao, Yunhe
Zhao, Faming
Bian, Hongjun
Yi, Wei
Yang, Jing
Li, Bin
Su, Guohai
Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China
title Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China
title_full Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China
title_fullStr Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China
title_full_unstemmed Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China
title_short Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China
title_sort hypertension may reduce the infection risk but increase the severity of covid-19: based on the current data in china
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685758/
https://www.ncbi.nlm.nih.gov/pubmed/34938578
http://dx.doi.org/10.1155/2021/6594863
work_keys_str_mv AT libo hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT zenglu hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT sunnengjun hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT zhaoyunhe hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT zhaofaming hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT bianhongjun hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT yiwei hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT yangjing hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT libin hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina
AT suguohai hypertensionmayreducetheinfectionriskbutincreasetheseverityofcovid19basedonthecurrentdatainchina